This update includes the fact that Cepheid ended the quarter with $82.2 million in marketable securities as well as $16.2 million in cash and equivalents.
 
NEW YORK (GenomeWeb News) — Cepheid today said third-quarter revenues increased 16 percent as R&D spending rose 17 percent and net loss increased 18 percent.
 
Total receipts for the three months ended Sept. 30 increased to $23.8 million from $20.4 million year over year.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.